Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Oct;30(4):519–526. doi: 10.1111/j.1365-2125.1990.tb03809.x

Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension.

P Minuz 1, S E Barrow 1, J R Cockcroft 1, J M Ritter 1
PMCID: PMC1368241  PMID: 2291866

Abstract

1. The effects of non-steroidal anti-inflammatory drugs (NSAID) on prostacyclin and thromboxane biosynthesis and on blood pressure were determined in 46 patients with mild essential hypertension. Patients who had abstained from antihypertensive therapy for 2 weeks before study were treated with either aspirin, ibuprofen, sulindac or placebo for 7 days. 2. Excretion rates of 2,3-dinor-6-oxo-prostaglandin (PG) F1 alpha, 6-oxo-PGF1 alpha, 2,3-dinorthromboxane (TX) B2 and TXB2 were measured as indices of prostacyclin and TXA2 biosynthesis. Samples were assayed using immunoaffinity chromatography and gas chromatography/electron capture chemical ionisation mass spectrometry. 3. Aspirin and ibuprofen reduced urinary excretion of all prostacyclin- and thromboxane-derived products. Sulindac inhibited excretion of 2,3-dinor-6-oxo-PGF1 alpha, 6-oxo-PGF1 alpha and 2,3-dinor-TXB2, but had no significant effect on TXB2. 4. Systolic blood pressure increased in the ibuprofen-treated group when compared with the placebo group. There were no other significant changes in systolic or diastolic pressure in any of the treatment groups. Among the patients as a whole, there was a significant negative correlation between change in blood pressure and change in excretion of the prostacyclin-derived but not of the thromboxane-derived products. 5. We conclude that, in patients with mild essential hypertension, neither sulindac nor aspirin (in the doses used) selectively spares prostacyclin biosynthesis by the kidney. The significant relationship between increase in blood pressure and reduction in prostacyclin biosynthesis favours the possibility that in individuals who become hypertensive, prostacyclin biosynthesis determines, in part, the severity of the hypertensive state.

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrow S. E., Ward P. S., Sleightholm M. A., Ritter J. M., Dollery C. T. Cigarette smoking: profiles of thromboxane- and prostacyclin-derived products in human urine. Biochim Biophys Acta. 1989 Oct 13;993(1):121–127. doi: 10.1016/0304-4165(89)90151-7. [DOI] [PubMed] [Google Scholar]
  2. Brater D. C., Anderson S., Baird B., Campbell W. B. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 1985 Jan;27(1):66–73. doi: 10.1038/ki.1985.11. [DOI] [PubMed] [Google Scholar]
  3. Bucchi F., Bodzenta A., de Gaetano G., Cerletti C. Effects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane B2 and 6-keto-PGF1 alpha in healthy subjects. Prostaglandins. 1986 Nov;32(5):691–701. doi: 10.1016/0090-6980(86)90191-7. [DOI] [PubMed] [Google Scholar]
  4. Burch R. M., Knapp D. R., Halushka P. V. Vasopressin stimulates thromboxane synthesis in the toad urinary bladder: effects of imidazole. J Pharmacol Exp Ther. 1979 Sep;210(3):344–348. [PubMed] [Google Scholar]
  5. Catella F., Nowak J., Fitzgerald G. A. Measurement of renal and non-renal eicosanoid synthesis. Am J Med. 1986 Aug 25;81(2B):23–29. doi: 10.1016/0002-9343(86)90905-8. [DOI] [PubMed] [Google Scholar]
  6. Ciabattoni G., Cinotti G. A., Pierucci A., Simonetti B. M., Manzi M., Pugliese F., Barsotti P., Pecci G., Taggi F., Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med. 1984 Feb 2;310(5):279–283. doi: 10.1056/NEJM198402023100502. [DOI] [PubMed] [Google Scholar]
  7. Cibattoni G., Boss A. H., Patrignani P., Catella F., Simonetti B. M., Pierucci A., Pugliese F., Filabozzi P., Patrono C. Effects of sulindac on renal and extrarenal eicosanoid synthesis. Clin Pharmacol Ther. 1987 Apr;41(4):380–383. doi: 10.1038/clpt.1987.44. [DOI] [PubMed] [Google Scholar]
  8. Duggan D. E., Hare L. E., Ditzler C. A., Lei B. W., Kwan K. C. The disposition of sulindac. Clin Pharmacol Ther. 1977 Mar;21(3):326–335. doi: 10.1002/cpt1977213326. [DOI] [PubMed] [Google Scholar]
  9. Dunn M. J., Gröne H. J. The relevance of prostaglandins in human hypertension. Adv Prostaglandin Thromboxane Leukot Res. 1985;13:179–187. [PubMed] [Google Scholar]
  10. Ferreira S. H., Moncada S., Vane J. R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol. 1971 Jun 23;231(25):237–239. doi: 10.1038/newbio231237a0. [DOI] [PubMed] [Google Scholar]
  11. FitzGerald G. A., Oates J. A., Hawiger J., Maas R. L., Roberts L. J., 2nd, Lawson J. A., Brash A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676–688. doi: 10.1172/JCI110814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hamberg M. Inhibition of prostaglandin synthesis in man. Biochem Biophys Res Commun. 1972 Nov 1;49(3):720–726. doi: 10.1016/0006-291x(72)90470-6. [DOI] [PubMed] [Google Scholar]
  13. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hornych A., Safar M., Bariéty J., Simon A., London G., Levenson J. Thromboxane B2 in borderline and essential hypertensive patients. Prostaglandins Leukot Med. 1983 Feb;10(2):145–155. doi: 10.1016/s0262-1746(83)80005-5. [DOI] [PubMed] [Google Scholar]
  15. Lopez-Ovejero J. A., Weber M. A., Drayer J. I., Sealey J. E., Laragh J. H. Effects of indomethacin alone and during diuretic or beta-adrenoreceptor-blockade therapy on blood pressure and the renin system in essential hypertension. Clin Sci Mol Med Suppl. 1978 Dec;4:203s–205s. doi: 10.1042/cs055203s. [DOI] [PubMed] [Google Scholar]
  16. Minuz P., Barrow S. E., Cockcroft J. R., Ritter J. M. Prostacyclin and thromboxane biosynthesis in mild essential hypertension. Hypertension. 1990 May;15(5):469–474. doi: 10.1161/01.hyp.15.5.469. [DOI] [PubMed] [Google Scholar]
  17. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 Feb 1;17(3-4):317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
  18. Patrono C., Dunn M. J. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987 Jul;32(1):1–12. doi: 10.1038/ki.1987.164. [DOI] [PubMed] [Google Scholar]
  19. Puddey I. B., Beilin L. J., Vandongen R., Banks R., Rouse I. Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects. Clin Sci (Lond) 1985 Sep;69(3):327–336. doi: 10.1042/cs0690327. [DOI] [PubMed] [Google Scholar]
  20. Ritter J. M., Cockcroft J. R., Doktor H. S., Beacham J., Barrow S. E. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. Br J Clin Pharmacol. 1989 Nov;28(5):573–579. doi: 10.1111/j.1365-2125.1989.tb03544.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Roberts D. G., Gerber J. G., Barnes J. S., Zerbe G. O., Nies A. S. Sulindac is not renal sparing in man. Clin Pharmacol Ther. 1985 Sep;38(3):258–265. doi: 10.1038/clpt.1985.168. [DOI] [PubMed] [Google Scholar]
  22. Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971 Jun 23;231(25):235–237. doi: 10.1038/newbio231235a0. [DOI] [PubMed] [Google Scholar]
  23. Steiness E., Waldorff S. Different interactions of indomethacin and sulindac with thiazides in hypertension. Br Med J (Clin Res Ed) 1982 Dec 11;285(6356):1702–1703. doi: 10.1136/bmj.285.6356.1702-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Stoff J. S. Prostaglandins and hypertension. Am J Med. 1986 Jan 17;80(1A):56–61. doi: 10.1016/0002-9343(86)90932-0. [DOI] [PubMed] [Google Scholar]
  25. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  26. Wong D. G., Spence J. D., Lamki L., Freeman D., McDonald J. W. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet. 1986 May 3;1(8488):997–1001. doi: 10.1016/s0140-6736(86)91271-7. [DOI] [PubMed] [Google Scholar]
  27. Ylitalo P., Pitkäjärvi T., Metsä-Ketelä T., Vapaatalo H. The effect of inhibition of prostaglandin synthesis on plasma renin activity and blood pressure in essential hypertension. Prostaglandins Med. 1978 Dec;1(6):479–488. doi: 10.1016/0161-4630(78)90118-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES